生物化学教学课件：Sensory-Immune sys.pptVIP

未来方向：个体化治疗 - 针对个体遗传和疾病分子分型 IRESSA IRESSA 口服EGFR酪氨酸激酶抑制剂 IRESSA 第一个被批准的EGFR酪氨酸激酶抑制剂，治疗进展期NSCLC IRESSA 的作用机制不同于细胞毒性化疗 NSCLC的EGFR-TK 结构域 (exons 18-24) 30多个突变 Lynch 等发现8/9 (89%)病例有很好的效果(50% 肿瘤缩小)，而这些肿瘤都有EGFR-TK 突变 NSCLC的EGFR-TK突变的频率相关; 女性，腺癌和日本族 5 病例IRESSA有效的病例中5例有EGFR-TK突变 EGFR-TK mutations and response to IRESSA * * 肿瘤治疗 前途光明；道路曲折 * 谢谢！ 祝各位同学前程似锦 * * * * * * IRESSA has received approval in many countries for use in patients with locally advanced or metastatic NSCLC who have received prior chemotherapy or who are not suitable for chemotherapy. IRESSA is included in NSCLC treatment guide